// App-Quantinova.ai

2481 : Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years

Researchers

Presenter

  • Gerd R. Burmester

Principal Investigators

  • Remo Panaccione

  • Kenneth B. Gordon

  • James T. Rosenbaum

  • Dilek Arikan

  • Winnie L. Lau

  • Rita Tarzynski-Potempa

Medical Centers

  • Charite-University Medicine Berlin, Berlin, Germany

  • University of Calgary, Calgary, AB, Canada

  • The Medical College of Wisconsin, Milwaukee, WI

  • Ophthalmology, Oregon Health & Science University and Legacy Devers Eye Institute, Portland, OR

  • AbbVie, Inc., North Chicago, IL

Locations

  • Germany

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved